Literature DB >> 23392464

Nevirapine inhibits the anti-HIV activity of CD8+ cells.

Lianxing Liu1, Lin Wang, Liusheng Huang, Vincent Siu, Fernando Teque, Francesca T Aweeka, Jay A Levy.   

Abstract

Antiretroviral therapy (ART) significantly reduced the CD8 cell noncytotoxic anti-HIV response in 12 HIV-1-infected subjects (P < 0.0001). In separate experiments, CD8(+) cells from long-term survivors were cocultured with HIV-infected CD4(+) cells using varying concentrations of anti-HIV drugs. The antiviral function of CD8(+) cells from 4 of the 14 LTSs was reduced with exposure to 10 μM of nevirapine (P < 0.05). The antiviral activity of CD8(+) cells from 2 LTSs was inhibited by 5 μM of zidovudine. These studies indicate that nevirapine and probably zidovudine can inhibit the anti-HIV activity of CD8(+) cells and thus could influence the effectiveness of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392464      PMCID: PMC3653990          DOI: 10.1097/QAI.0b013e318289822d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  27 in total

1.  An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma.

Authors:  Jingduan Chi; Anura L Jayewardene; Judith A Stone; Francesca T Aweeka
Journal:  J Pharm Biomed Anal       Date:  2003-04-01       Impact factor: 3.935

2.  Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy.

Authors:  Robert Weinkove; Savita Rangarajan; Jon van der Walt; Ranjababu Kulasegaram
Journal:  AIDS       Date:  2005-11-18       Impact factor: 4.177

3.  Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

Authors:  S Colombo; A Beguin; A Telenti; J Biollaz; T Buclin; B Rochat; L A Decosterd
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-05-25       Impact factor: 3.205

4.  Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection.

Authors:  Davey Smith; Niousha Moini; Rick Pesano; Edward Cachay; Heidi Aiem; Yolanda Lie; Douglas Richman; Susan Little
Journal:  Clin Infect Dis       Date:  2006-12-28       Impact factor: 9.079

5.  Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.

Authors:  M A Vodicka; W C Goh; L I Wu; M E Rogel; S R Bartz; V L Schweickart; C J Raport; M Emerman
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

6.  The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

Authors:  J M Binley; A Trkola; T Ketas; D Schiller; B Clas; S Little; D Richman; A Hurley; M Markowitz; J P Moore
Journal:  J Infect Dis       Date:  2000-08-01       Impact factor: 5.226

7.  Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals.

Authors:  JoAnn C Castelli; Steven G Deeks; Stephen Shiboski; Jay A Levy
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

8.  Zidovudine induced pure red cell aplasia: a case report.

Authors:  A Hassan; A A Babadoko; A I Mamman; S A Ahmed
Journal:  Niger J Med       Date:  2009 Jul-Sep

9.  Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.

Authors:  Raoul Moh; Christine Danel; Eugène Messou; Timothée Ouassa; Delphine Gabillard; Amani Anzian; Yao Abo; Roger Salamon; Emmanuel Bissagnene; Catherine Seyler; Serge Eholié; Xavier Anglaret
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

10.  Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.

Authors:  S A Stranford; J C Ong; B Martinez-Marino; M Busch; F M Hecht; J Kahn; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.